After capital expenditures and dividend payments have been made, Roche has generated excess
free cash flow of almost $ 22 billion combined from 2012 - 2014, indicating the company is a strong
cash flow generator and the dividend is secure.
Medtronic is a consistent
generator of
free cash flow, even following the Covidien acquisition, although the acquisition caused a drop in the absolute numbers.